The Klarna Conundrum: Soaring Business Metrics, Plunging Share Price

Klarna's share price hits 52-week lows despite operational records, as losses fuel investor skepticism. Insiders buy heavily while major banks cut price targets.

A striking divergence is unfolding at Klarna. The Swedish payments giant is announcing one operational record after another, yet its stock is being ruthlessly sold off on the exchange. This glaring disconnect between fundamental performance and market valuation has now drawn significant action from prominent company insiders.

The share price chart paints a bleak picture. Since the start of the year, the equity has shed nearly 55% of its value, trading just barely above its 52-week low of €10.86. This sell-off occurs against a backdrop of robust business achievements. This week, Klarna's physical card surpassed the milestone of five million active users globally. Simultaneously, its merchant network broke through the one million connected retailers threshold, representing substantial annual growth of 47%.

Profitability Remains Elusive Amid Rapid Expansion

The root of investor skepticism is buried within the company's financials from the past year. While processed payment volume grew by 22% to nearly $128 billion and revenues climbed to $3.5 billion, the bottom line tells a different story. Klarna reported a full-year 2025 loss per share of -$0.79. Its aggressive growth strategy is weighing heavily on profitability, creating clear nervousness in an interest rate-sensitive market environment.

Leadership Buys as Analysts Revise Targets

As the broader market exits, company executives are stepping in to buy shares at what they see as a discounted level. Leading the charge is Supervisory Board Chairman Michael Moritz, who in early March purchased stock worth almost $50 million. The company's Chief Product Officer also increased his position. Major Wall Street institutions, however, are exhibiting pronounced caution. Responding to persistent volatility, they have issued a wave of price target reductions in recent days:

• UBS and JPMorgan: Lowered target to $20.00
• Morgan Stanley: Reduced target to $23.00
• Keefe, Bruyette & Woods: Adjusted target to $26.00
• Wells Fargo: Set a new target of $32.00

Despite these downward revisions, even the most pessimistic price forecast from these firms remains significantly above the stock's current trading level. The analyst consensus maintains a medium-term optimistic view, with eleven "buy" ratings compared to just a single "sell" recommendation. The substantial insider buying by management underscores this stance and establishes a clear counterbalance to the ongoing selling pressure on the exchange.